Free Trial
NASDAQ:LSB

Lakeshore Biopharma (LSB) Stock Price, News & Analysis

Lakeshore Biopharma logo
$1.07 -0.01 (-0.93%)
Closing price 05/30/2025 03:39 PM Eastern
Extended Trading
$1.07 0.00 (0.00%)
As of 05/30/2025 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lakeshore Biopharma Stock (NASDAQ:LSB)

Key Stats

Today's Range
$1.07
$1.08
50-Day Range
$1.05
$2.69
52-Week Range
$0.99
$9.99
Volume
5,878 shs
Average Volume
20,207 shs
Market Capitalization
$9.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

Lakeshore Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

LSB MarketRank™: 

Lakeshore Biopharma scored higher than 11% of companies evaluated by MarketBeat, and ranked 900th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Lakeshore Biopharma.

  • Percentage of Shares Shorted

    0.08% of the float of Lakeshore Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lakeshore Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lakeshore Biopharma has recently increased by 64.71%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Lakeshore Biopharma does not currently pay a dividend.

  • Dividend Growth

    Lakeshore Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.08% of the float of Lakeshore Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lakeshore Biopharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lakeshore Biopharma has recently increased by 64.71%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Lakeshore Biopharma has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lakeshore Biopharma this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Lakeshore Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    52.64% of the stock of Lakeshore Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lakeshore Biopharma's insider trading history.
Receive LSB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lakeshore Biopharma and its competitors with MarketBeat's FREE daily newsletter.

LSB Stock News Headlines

Elon’s backup plan for AI
Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.
LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval
See More Headlines

LSB Stock Analysis - Frequently Asked Questions

Lakeshore Biopharma's stock was trading at $3.46 at the beginning of the year. Since then, LSB shares have decreased by 69.1% and is now trading at $1.07.
View the best growth stocks for 2025 here
.

Lakeshore Biopharma's stock reverse split on Friday, October 4th 2024. The 1-10 reverse split was announced on Friday, September 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of LSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lakeshore Biopharma investors own include Jiuzi (JZXN), Aethlon Medical (AEMD), Aditxt (ADTX), Adial Pharmaceuticals (ADIL), Avalon GloboCare (ALBT), Ainos (AIMD) and AMC Entertainment (AMC).

Company Calendar

Today
6/01/2025
Next Earnings (Estimated)
8/18/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LSB
Previous Symbol
NASDAQ:LSB
Web
N/A
Fax
N/A
Employees
773
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$672.27 million
Price / Cash Flow
N/A
Book Value
$8.86 per share
Price / Book
0.12

Miscellaneous

Free Float
N/A
Market Cap
$9.96 million
Optionable
N/A
Beta
0.64
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:LSB) was last updated on 6/1/2025 by MarketBeat.com Staff
From Our Partners